Accessibility Menu
 
Capricor Therapeutics logo

Capricor Therapeutics

(NASDAQ) CAPR

Current Price$35.07
Market Cap$2.03B
Since IPO (2013)-16%
5 Year+800%
1 Year+166%
1 Month+18%

Capricor Therapeutics Financials at a Glance

Market Cap

$2.03B

Revenue (TTM)

$0.00

Net Income (TTM)

$105.04M

EPS (TTM)

$-2.26

P/E Ratio

-15.63

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$35.07

Volume

35,567

Open

$35.18

Previous Close

$35.07

Daily Range

$34.14 - $35.19

52-Week Range

$4.30 - $40.37

CAPR News

CAPR: Motley Fool Moneyball Superscore

61

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Capricor Therapeutics

Industry

Biotechnology

Employees

231

CEO

Linda Marbán, PhD

Headquarters

San Diego, CA 92121, US

CAPR Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-47%

Return on Capital

-34%

Return on Assets

-30%

Earnings Yield

-6.40%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.03B

Shares Outstanding

57.51M

Volume

35.57K

Short Interest

0.00%

Avg. Volume

1.25M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$108.14M

EBITDA

$108.14M

Operating Cash Flow

$69.81B

Capital Expenditure

$2.90B

Free Cash Flow

$72.72B

Cash & ST Invst.

$318.13M

Total Debt

$20.94M

Capricor Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$2.03B

N/A

Market Cap/Employee

$12.68M

N/A

Employees

160

N/A

Net Income

$30.17M

-324.0%

EBITDA

$29.16M

-298.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$297.18M

+98.0%

Accounts Receivable

$59.17K

-99.4%

Inventory

$0.00

N/A

Long Term Debt

$14.32M

+2223.6%

Short Term Debt

$6.62M

+693.5%

Return on Assets

-29.51%

N/A

Return on Invested Capital

-33.78%

N/A

Free Cash Flow

$28.69M

-84.7%

Operating Cash Flow

$23.57M

-59.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALLOAllogene Therapeutics, Inc.
$2.25-2.60%
TRDAEntrada Therapeutics, Inc.
$12.96+2.61%
LXEOLexeo Therapeutics, Inc. Common Stock
$5.63-3.85%
VNDAVanda Pharmaceuticals Inc.
$6.79-1.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.77+0.03%
OGNOrganon & Co.
$13.18+0.17%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.32+0.01%
TSLATesla
$378.56+0.01%

Questions About CAPR

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.